M&A Deals Sparks Healthcare Sector: Lincare Holdings, Amylin Pharmaceuticals, Ampio Print E-mail
By Staff and Wire Reports   
Monday, 02 July 2012 12:26
icon_NewsMakersUPLincare Holdings Inc.(NASDAQ:LNCR) has topped the percentage list on buyout news and soared 21.44% to $41.31 after hitting a 52-week high of $41.35. This weekend, Linde AG agreed to acquire the company for about $4.6 billion, payable in cash.

Also, in the merger & acquisition news, Brightpoint, Inc.(NASDAQ:CELL) agreed to be acquired by Ingram Micro Inc. in exchange of $9 per share in cash. The transaction valued the company at about $840 million, including estimated net debt of $190 million on June 30. Post deal, Ingram projecting to boost its EPS by 18 cents in 2013 and 35 cents in 2014, excluding one-time charges and integration costs.Shares of CELL soared over 63% to $8.83.

Ampio Pharmaceuticals, Inc.(NASDAQ:AMPE) is another stock which is showing solid up move with a gain of 11.22% to $5.65. The company announced an agreement with India-based Syngene to create a combination product to treat both premature ejaculation and erectile dysfunction in a Phase III trial. The resulted product would be known as Zertane-ED, will be used in trials in South Korea with the biopharmaceutical company's partner Daewoong Co., which will finance and conduct the trials.

Amylin Pharmaceuticals, Inc.(NASDAQ:AMLN) added 8.83% to $30.69 and made a new 52-week high of $30.75. This morning Bristol Myers Squibb Co.(NYSE:BMY) agreed to buy the company for $5.3 billion or $31 per share in cash.

Following an acquisition of Amylin, analyst at Piper Jaffray issued a positive note on various biotech stocks and stated those companies would be an acquisition target. BioMarin Pharmaceutical Inc.(NASDAQ:BMRN) climbed 1.47 (3.71%) to $41.05, Theravance Inc(NASDAQ:THRX) added 1.77 (7.94%) at $23.99, Affymax, Inc.(NASDAQ:AFFY) rose 0.19 (1.48%) to $13.07 and Rigel Pharmaceuticals, Inc.(NASDAQ:RIGL) surged 0.13 (1.40%) to $9.43.

Cytori Therapeutics Inc. (USA)(NASDAQ:CYTX) extended its uptrend and rose another 9.26% to $2.95. The stock has been showing solid buying since early July and went up all the way from $2.05 to $2.95 in about a month. In February, the stock had sharp selloff and lost  about 50% in just one month.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus